The Study on the Dilution Time of Radioactive Tracer in Estradiol Measurement

방사성 요오드 치료 후, 퇴원 선량 측정에 있어 각국의 기준 및 권고 비교

  • Lee, Seung Jae (Department of Nuclear Medicine, Severance Hospital, Yonsei University Health System) ;
  • Seo, Soo Hyun (Radiation Safety Center, Yonsei University) ;
  • Lee, Sung Ha (Department of Nuclear Medicine, Severance Hospital, Yonsei University Health System) ;
  • Park, Yong Sung (Department of Radiology, Kyung Hee University Hospital at Gangdong) ;
  • Oh, Ki Baek (Department of Nuclear Medicine, Severance Hospital, Yonsei University Health System) ;
  • Kim, Jae Sam (Department of Nuclear Medicine, Severance Hospital, Yonsei University Health System)
  • 이승재 (연세의료원 세브란스병원 핵의학과) ;
  • 서수현 (연세대학교 방사선안전관리센터) ;
  • 이성하 (연세의료원 세브란스병원 핵의학과) ;
  • 박용성 (강동경희대학교병원 영상의학과) ;
  • 오기백 (연세의료원 세브란스병원 핵의학과) ;
  • 김재삼 (연세의료원 세브란스병원 핵의학과)
  • Received : 2017.09.29
  • Accepted : 2017.10.20
  • Published : 2017.11.11

Abstract

Purpose The high-dose administration of I-131 has been standing for the basic therapy method of thyroid cancer. In korea, it is not necessary for patients to be hospitalized if the administration dose are under 1.2 GBq. However, if the dose are over 1.2 GBq, the patients should be stay in special ward with radiation shield. In such cases, the radioactivity level upon release should be under a dose of $70{\mu}Sv/hr$ at a distance of approx. 1m. This regulation bring the patients to stay for about 2 to 3 days in ward before the release. Materials and Methods Using the inpatients' release data of severance hospital, an inpatient-days were retrospectively calculated and compared with practical data and estimate the inpatient-days with the conditions of korea ($70{\mu}Sv/hr$), Japan ($30{\mu}Sv/hr$), germany ($3.5{\mu}Sv/hr$ at a distance of approx. 2 m), and other european countries. Results When a effective half-life of 15.4 was used, the expected inpatient-days were calculated as 2.15 days in the condition of Japanese regulation and 1.37 days in the condition of korean regulation. The practical inpatient-days of patients in Severance hospital were 1.32 days. Conclusion As ICRP 94 has been mentioned that the release of patients administrated with I-131 for the therapy should be carefully considered because each patients has different thyroid uptake rate and their conditions with family members after the release from the ward. Nonetheless, efforts to bring more aquate data which is for getting closer to the practical data should be continuously studied.

Keywords

References

  1. Journal of Cancer Epidemiology.
  2. Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors
  3. S.G. Park, MD. Effective Half-life of I-131 in Patients with Differentiated Thyroid Cancer Treated by Radioactive I-131, Nuclear Medicine Molecular Imaging Vol. 42, No. 6, Dec 2008
  4. North D, Shearer DR, Hennessey JV, Donovan GL. Effective half-life of 131I in thyroid cancer patients. Health Physics 2001;81:325-9. https://doi.org/10.1097/00004032-200109000-00013